Characterisation of pharmacokinetics, safety and tolerability in a first-in-human study for AZD8154, a novel inhaled selective PI3Kγδ dual inhibitor targeting airway inflammatory disease.
Sadiq MW, Asimus S, Belvisi MG, Brailsford W, Fransson R, Fuhr R, Hagberg A, Hashemi M, Jellesmark Jensen T, Jonsson J, Keen C, Körnicke T, Kristensson C, Mäenpää J, Necander S, Nemes S, Betts J.
Sadiq MW, et al. Among authors: fuhr r.
Br J Clin Pharmacol. 2022 Jan;88(1):260-270. doi: 10.1111/bcp.14956. Epub 2021 Aug 8.
Br J Clin Pharmacol. 2022.
PMID: 34182611
Free article.
Clinical Trial.